Live Breaking News & Updates on Bodor Laboratories Inc|Page 3

Published: Jan 19, 2021
BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) Brickell Biotech Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that the efficacy and safety results from the pivotal Phase 3 study conducted in Japan by its development partner, Kaken Pharmaceutical Co., Ltd. (“Kaken”) were published in the peer-reviewed Journal of Dermatology
1.
The paper, entitled “A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis,” is available online in English at the Wiley Online Library (click here). ....

United States , Nicholas Bodor , Deepak Chadha , Research Professor , Brickell Biotech Inc , Wiley Online Library , Japanese Dermatological Association , International Hyperhidrosis Society , Bodor Laboratories Inc , Asian Dermatological Association , Kaken Pharmaceutical Co Ltd , University Of Florida , Exchange Commission , Chief Research , Development Officer , Bodor Laboratories , Graduate Research Professor Emeritus , Securities Litigation Reform Act , United States Securities , Asian Dermatological , Arch Dermatol Res , Investor Contact , Brickell Biotech Announces Publication Of Japan Pivotal Phase 3 Study Results For Sofpironium Bromide Gel , 5 Ecclock In The Journal Of Dermatology , ஒன்றுபட்டது மாநிலங்களில் , தீபக் சதா ,